Hikma Pharmaceuticals Plc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hikma Pharmaceuticals PLC is a multinational pharmaceutical company that develops, manufactures and markets generic, branded generic and in-licensed products, including sterile injectables, oral solids, nasal sprays, respiratory products and biosimilars; it supplies over 800 medicines across therapeutic areas such as oncology, pain management, cardiovascular, diabetes, central nervous system, dermatology and respiratory to hospitals, clinics and retail markets. Hikma operates through three main segments--Injectables, which provides generic and specialty injectable medicines to North America, Europe and MENA; Branded, which offers branded generics and in-licensed patented products primarily in MENA; and Generics (Hikma Rx), which delivers oral, respiratory and specialty generics to the North American retail market--with manufacturing facilities in the US (Ohio, New Jersey), six MENA countries, Portugal, Italy, Germany and Jordan. The company, founded in 1978 and headquartered in London, UK, serves over 50 countries with a focus on North America, MENA and Europe. Recent developments include the acquisition of Xellia Pharmaceuticals' US finished dosage business in 2024 to strengthen injectables; agreement to acquire 17 Takeda brands licensed to Hikma; $1 billion US investment announced in June 2025 for manufacturing and R&D expansion in Ohio and New Jersey; $250 million financing deal with IFC in July 2025 to boost MENA operations; exclusive US partnership with Emergent BioSolutions for Kloxxado naloxone nasal spray in January 2025; exclusive MENA agreement with DGI Group for Claritag in November 2025; strengthened partnership with Celltrion for biosimilars in October 2025; launch of STARJEMZA ustekinumab biosimilar and liraglutide GLP-1 injection in the US in November 2025; centralisation of global R&D under a new structure in November 2025; and confirmation of 2025 revenue growth guidance of 4-6% with core operating profit of $730-750 million.
Company News
Hikma Pharmaceuticals PLC (HKMPY) Discusses R&D Vision and Expansion in Respiratory, Nasal, Semi-Solids and Liquid Platforms Transcript
Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Panmure Liberum raises Hikma target price to 1,900p
Jefferies lifts Hikma target as CMO deal underpins growth story
Citi sees Hikma discount as unwarranted after upgrade to forecasts
Hikma boost as broker raises price target
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Prepared Remarks Transcript
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma recovery story still has further to run after recent rally, says Panmure
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript